GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NGM282

Company
NGM Biopharmaceuticals, Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01776528

    Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

    Not yet reported NGM Biopharmaceuticals, Inc 119 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01943045

    Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

    Not yet reported NGM Biopharmaceuticals, Inc 81 participants Est. completion 2014-09 9 sites Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02026401

    Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

    Not yet reported NGM Biopharmaceuticals, Inc 45 participants Est. completion 2014-12 17 sites Stand-alone
    Other conditions: Primary Biliary Cirrhosis
    View official trial listing →
  • Completed NCT NCT02135536

    Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

    Not yet reported NGM Biopharmaceuticals, Inc 36 participants Est. completion 2016-02 17 sites Stand-alone
    Other conditions: Primary Biliary Cirrhosis
    View official trial listing →
  • Completed NCT NCT02443116

    Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

    Not yet reported NGM Biopharmaceuticals, Inc 254 participants Est. completion 2020-01-17 22 sites Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT02649062

    Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

    Not yet reported, Not yet reported NGM Biopharmaceuticals, Inc 31 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Functional Constipation
    View official trial listing →
  • Completed NCT NCT02704364

    A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

    Not yet reported NGM Biopharmaceuticals, Inc 62 participants Est. completion 2017-06 38 sites Stand-alone
    Other conditions: Primary Sclerosing Cholangitis
    View official trial listing →
  • Completed NCT NCT03912532

    Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

    Not yet reported NGM Biopharmaceuticals, Inc 171 participants Est. completion 2021-03-29 37 sites Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT04179630

    Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

    Not yet reported NGM Biopharmaceuticals, Inc 48 participants Est. completion 2019-12-14 1 site Stand-alone
    Other conditions: Impaired Renal Function
    View official trial listing →
  • Completed NCT NCT04210245

    Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

    Not yet reported NGM Biopharmaceuticals, Inc 160 participants Est. completion 2023-02-23 49 sites
    MASH Other conditions: Compensated Cirrhosis
    View official trial listing →
  • Completed NCT NCT04823702

    Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

    Not yet reported NGM Biopharmaceuticals, Inc 36 participants Est. completion 2021-11-19 3 sites Stand-alone
    Other conditions: Impaired Hepatic Function
    View official trial listing →
  • Completed NCT NCT04828265

    Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

    Not yet reported NGM Biopharmaceuticals, Inc 36 participants Est. completion 2021-07-06 1 site
    Other conditions: Healthy Male
    View official trial listing →
  • Completed NCT NCT05130047

    Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

    Not yet reported Michael Camilleri, MD 30 participants Est. completion 2022-11-08 1 site Stand-alone
    Other conditions: Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.